In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Prognosis of patients with cardiac amyloidosis referred in the French cardiac amyloidosis expert center.
2017

Congress : ESC Congress

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Myocardial Disease – Clinical
  • Session type : Moderated Posters
  • FP Number : P5845

Authors : T Damy (Creteil,FR), A Galat (Creteil,FR), S Rouffiac (Creteil,FR), S Guendouz (Creteil,FR), M Kharoubi (Creteil,FR), K Ayad (Creteil,FR), N De Nadai (Creteil,FR), V Plante-Bordeneuve (Creteil,FR), F Lebras (Creteil,FR), A Amiot (Creteil,FR), C Radu (Creteil,FR), JL Dubois-Rande (Creteil,FR), D Bodez (Creteil,FR)

15 views

Authors:
T. Damy1 , A. Galat2 , S. Rouffiac2 , S. Guendouz2 , M. Kharoubi2 , K. Ayad2 , N. De Nadai2 , V. Plante-Bordeneuve2 , F. Lebras2 , A. Amiot2 , C. Radu2 , J.L. Dubois-Rande2 , D. Bodez2 , 1AP-HP - University Hospital Henri Mondor - Creteil - France , 2GRC-Amyloid Research Institute - APHP - INSERM - Creteil - France ,

On behalf: GRC Amyloid Research Insitute

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 1237-1238

Introduction: Amyloidosis is a disease caused by infiltration of tissues by an amyloid protein. The most frequent cardiac amyloidosis are light chain (AL) amyloidosis, hereditary transthyretin (TTR-h) and wild transthyretin (w-TTR).

Objective: Describe baseline clinical, biological, echocardiographic characteristics and prognostic of patients referred for cardiac amyloidosis in the Amyloidosis expert cente.

Methods: From 2010 to July 2016, all patients referred to the expert center of our Hospital for suspected cardiac amyloidosis were included. Baseline demographic, clinical, laboratory and ultrasound characteristics were recorded and patients were followed-up for major events including death, cardiac transplantation and left ventricular assistance implant.

Results: Of the 942 patients referred for suspicion of CA, 502 had confirmed CA of whom162 had AL amyloidosis, 203 h-TTR and 141 w-TTR. CA were men in 60%, the median age was 69 years w-TTR amyloidosis were older (83 [79; 87], p<0.001) and more men (86%, p<0.001) than the two other types of CA. NYHA III-IV dyspnea was more frequent in AL amyloidosis (60%) and w-TTR (54%, p<0.001)compared to h-TTR, while neurological symptoms were more predominant in h-TTR (62% p<0.001). Creatinine, NT-proBNP and troponin were higher in AL amyloidosis and w-TTR (p<0.001) than in h-TTR. w-TTR amyloidosis had thicker Interventricular septum thicker, lower LVEF, higher global strain E/A and E/Ea ratios than the two other types of CA (p<0.001). During follow-up 137 major events occured. Median follow-up was 22 (8–36) months. The survival without major event was 59% for AL amyloidosis, 79% for w-TTR, 81% for h-TTR versus 88% for patients without amyloidosis (p<0.001). In multivariate analysis, only NYHA class III-IV, hyponatremia, elevation of creatinine, troponin and NTproBNP were independent prognostic factors (p<0.001).

Conclusion: Cardiac amyloidosis is more frequent than initially thought, with very different layouts depending on the type of amyloid protein involved. Its prognosis is poor at short term. The challenge is to achieve earlier diagnosis to improve prognosis

Please login to My ESC

This content may be restricted, please sign in to check your access.

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are